Entropy Technologies LP Purchases 2,259 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Entropy Technologies LP raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 69.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 5,500 shares of the company’s stock after acquiring an additional 2,259 shares during the period. Entropy Technologies LP’s holdings in IDEXX Laboratories were worth $2,274,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. International Assets Investment Management LLC grew its position in IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock valued at $2,669,890,000 after purchasing an additional 527,460 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after buying an additional 316,048 shares during the last quarter. Seilern Investment Management Ltd bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $113,104,000. Vontobel Holding Ltd. raised its holdings in shares of IDEXX Laboratories by 3,325.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock worth $111,229,000 after acquiring an additional 213,731 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC lifted its position in IDEXX Laboratories by 230.1% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 110,196 shares of the company’s stock valued at $55,673,000 after acquiring an additional 76,809 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now directly owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.11% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have commented on IDXX. Leerink Partners assumed coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. Bank of America raised their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Morgan Stanley reduced their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Barclays raised their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $524.38.

IDEXX Laboratories Stock Down 0.2 %

IDXX opened at $459.78 on Monday. The company’s 50-day moving average price is $428.35 and its two-hundred day moving average price is $453.44. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The stock has a market cap of $37.65 billion, a price-to-earnings ratio of 43.09, a PEG ratio of 3.47 and a beta of 1.37.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.